---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-258963"
form_type: "8-K"
ticker: "BEAM"
cik: "0001745999"
company_name: "Beam Therapeutics Inc."
filed_at: "2023-10-19T23:59:59+00:00"
generated_at: "2026-06-09T20:59:00.520096+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Beam cuts ~20% workforce (100 roles), focuses on sickle cell, AATD, extends cash runway into 2026

## Summary
- Reduces headcount by ~100 employees (20%), expects $6.6M in Q4 2023 severance costs.
- Prioritizes BEAM-101, ESCAPE, and in vivo sickle cell programs; BEAM-302 for AATD.
- Explores partnerships for BEAM-201 and other CAR-T programs; pauses hepatitis B program.
- Cash, equivalents, and securities of $1.1B (June 30, 2023) expected to fund operations into 2026.
- Strategic restructuring aims to streamline operations and focus on near-term value drivers.

## SEC filing metadata
- accession: 0001193125-23-258963
- form_type: 8-K
- ticker: BEAM
- cik: 0001745999
- company_name: Beam Therapeutics Inc.
- filed_at: 2023-10-19T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.05, 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1745999/000119312523258963/0001193125-23-258963-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1745999/000119312523258963/d517250d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-258963
- JSON: https://secwatch.observer/filing/0001193125-23-258963.json
- Plain text: https://secwatch.observer/filing/0001193125-23-258963.txt

## Key facts
- Restructurings & Charges
  Beam Therapeutics Inc. announced a restructuring with charges of approximately $6.6 million affecting not explicitly stated per segment, but described as portfolio prioritization and strategic restructuring of Beam Therapeutics (approximately 100 positions, or about 20% of its workforce).
  - Type: restructuring
  - Charge: approximately $6.6 million
  - Affected area: not explicitly stated per segment, but described as portfolio prioritization and strategic restructuring of Beam Therapeutics
  - Headcount: approximately 100 positions, or about 20% of its workforce
  source text: the Company expects to reduce its employee headcount by approximately 100 positions, or about 20% of its workforce. The Company expects to incur one-time costs of approximately $6.6 million in the fourth quarter of 2023 in connection with the workforce reduction. These costs consist primarily of cash expenditures related to severance payments. The Company estimates
  evidence_url: https://www.sec.gov/Archives/edgar/data/1745999/000119312523258963/0001193125-23-258963-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.